MPL and acute myeloid leukemia: Besides the MA9 model, we evaluated outcomes by inducing Prmt9 KD in another CBFB-MYH11 knock-in AML model plus thrombopoietin receptor transduction (namely, CMM)24,25 resembling inv (16) AML.